Immuneering Corp (IMRX) stock forecast and price target
Price $3.71 · data as of November 13, 2026
12-month price target
Average target$17.00
Upside / downside+358.2%
Analysts6
ConsensusStrong buy
Low $11.00Average $17.00High $30.00
Gold marker: average target · white marker: today’s price ($3.71)
Analyst ratings
Strong buy 2Buy 5Hold 0Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-1.26 | +1.0% | $0 |
| Next fiscal year ends December 31, 2027 | $-1.64 | −30.6% | $0 |
| Next quarter ends December 31, 2026 | $-0.41 | −126.2% | $0 |
| Quarter after ends March 31, 2027 | $-0.40 | −88.9% | $0 |
Consensus of the analysts covering Immuneering, updated daily. In the last 30 days 0 estimates were raised and 2 lowered.
Frequently asked questions
What is the Immuneering stock price target?
The average 12-month target from 6 analysts is $17.00, 358.2% above the current price of $3.71 Targets range from $11.00 to $30.00.
Is Immuneering a buy according to analysts?
The consensus rating is “Strong buy” (2 strong buy, 5 buy). Ratings are opinions, not guarantees; this is not investment advice.
How much is Immuneering expected to earn?
Analysts expect EPS of $-1.26 for the fiscal year ending December 31, 2026 and $-1.64 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.